Delivery Order SPE2DB22D1106-SPE2DB25FEYN0
- Not listed
- This is a $13,191.68 firm fixed price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of ACTEMRA 400 MG/20 ML VIAL 20ML. The contract has an ultimate completion date of May 19, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract valued at $6,428.06 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the provision of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty pharmaceutical product, with a delivery date of April 4, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,109,223 units of the pharmaceutical product ACTEMRA 400 MG/20 ML VIAL 20ML. The contract has a ceiling value of $11,253.17 and a period of performance through March 29, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,946.84, is a Delivery Order for the ACTEMRA 400 MG/20 ML VIAL 20ML pharmaceutical product. The contract has an ultimate completion date of November 4, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division, located in Conshohocken, Pennsylvania. The $13,154.40 contract is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty pharmaceutical product, in support of military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary...
- This is a $12,081.70 firm-fixed price delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a pharmaceutical product, with a performance period through July 16, 2025. The contract is not set aside and represents an open competition. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,571.72 firm fixed price delivery order contract, awarded on October 16, 2024, is for the supply of ACTEMRA 400 MG/20 ML VIAL 20ML, a specialty medication. The contract has an ultimate completion date of October 17, 2024 and was not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,233.43 firm fixed-price delivery order is for the supply of ACTEMRA 400 MG/20 ML VIAL 20ML, a specialty pharmaceutical product. The contract has an ultimate completion date of December 27, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a $8,217.76 firm fixed-price delivery order awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ACTEMRA 400 MG/20 ML VIAL 20ML, a specialty medication, with a completion date of February 13, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. This $6,243.29 contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML pharmaceutical products. The contract has an ultimate completion date of April 12, 2024. AmerisourceBergen Drug Corp is the prime contractor and there is no set-aside designation for this award. This delivery...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEYN0Delivery Order
The Defense Logistics Agency (DLA) awarded a $13,171.30 delivery order to AmerisourceBergen Drug Corp for 4,568,832,740 units of Actemra 400 mg/20 mL vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio demonstrates capability to fulfill federal medical supply needs through competitive procurement, with delivery orders consistently structured as firm fixed-price arrangements. Actemra (tocilizumab) is a biologic immunosuppressant used in the treatment of various inflammatory and autoimmune conditions, and this delivery order represents a component of the company's ongoing pharmaceutical supply obligations to support military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.2k | 7/18/25 |